Anthropic slows frontier R&D as 2 states push AI kill switches

source:

[1] Anthropic's CEO: The company will slow down the pace of AI R&D due to safety concerns (https://wallstreetcn.com/articles/3782400 ...)[2] Governor Newsom announces world-leading experts to deliver on his AI executive order, including advancing creation of a “kill switch” (https://www.gov.ca.gov/2026/09/23/governor-ne ...)

Related News

Sep 23 2026, 21:02

Viking Therapeutics raises $400 million as VKTX dilution risk builds

Viking Therapeutics plans to sell $200.0 million of common stock alongside $200.0 million of convertible senior notes maturing in 2032, a $400.0 million dual raise that adds both new shares and new debt to a company with no marketed product. The two offerings are separate and neither is contingent on the other closing, the San Diego-based company said in a Sept. 23 statement. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are joint book-running managers on both. Each offering carries a 30-day underwriter option for an additional $30.0 million, which would lift the total to $460.0 million if fully exercised. "The completion of the common stock offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock offering," Viking said in the statement. The convertible notes are senior unsecured obligations that pay interest semiannually and mature Oct. 15, 2032. Viking can settle conversions in cash, stock, or a mix at its own election — a provision that lets the company cap share issuance if the stock rallies but leaves holders exposed to whatever mix Viking chooses. The interest rate, initial conversion rate, and conversion price will not be set until pricing. Viking may redeem the notes for cash on or after Oct. 22, 2029, but only if the stock trades above 130% of the conversion price for a specified period. A separate "cleanup" call lets Viking redeem the notes in whole if fewer than 15% of the original principal remains outstanding. ## The dilution math lands on a pre-revenue balance sheet Viking has no approved drug and no product revenue. Its lead asset, VK2735, is a dual GLP-1 and GIP receptor agonist — the same mechanism class as Eli Lilly's tirzepatide, sold as Zepbound and Mounjaro — being tested in Phase 3 obesity trials in both subcutaneous and oral formulations. The company is also advancing VK3019, an amylin receptor agonist, plus VK2809, an oral thyroid hormone receptor beta agonist, and VK0214 for X-linked adrenoleukodystrophy. That pipeline is funded entirely by capital markets. Viking did not disclose its cash balance, share count, or the resulting dilution percentage in the offering announcement, and the preliminary prospectus supplements filed with the SEC are the only place those figures will appear. The company said proceeds will fund continued clinical development, advancement, and commercialization of VK2735, continued development of VK3019, and general research, working capital, and corporate purposes. The structure matters more than the headline number. A straight $400.0 million equity sale would dilute holders immediately and permanently. Splitting the raise in half defers part of the cost: the convertible only converts if the stock clears the conversion price, so Viking pays interest instead of handing over shares if the shares stay weak. The trade-off is a debt claim sitting ahead of equity in the capital structure, plus a redemption trigger at 130% of the conversion price that effectively caps how much of a rally equity holders capture before the notes convert. ## Peers have already repriced on the same playbook Viking is not the first obesity-focused developer to tap both markets at once. The sector's clinical-stage names have leaned on convertibles repeatedly as GLP-1 competition intensified, and the pattern is consistent: the equity tranche prices at a discount to the last close, the convertible tranche prices with a conversion premium, and the stock trades lower into and after pricing. The competitive backdrop sharpens the read. Lilly and Novo Nordisk control the marketed GLP-1 market, while Amgen, Pfizer, Roche, and AstraZeneca are all funding their own obesity programs. Viking's pitch is efficacy and tolerability in a market where the incumbents already have manufacturing scale, payer relationships, and commercial infrastructure that a clinical-stage company would have to build or buy. That is precisely why the cash is needed — and precisely why the market prices the dilution before the data. For investors, the near-term question is arithmetic, not science. The offering price on the equity tranche, the conversion premium on the notes, and the updated share count in the prospectus supplement will determine the actual cost to existing holders. Until those terms price, VKTX holders are carrying an unquantified dilution overhang plus a new senior claim on the balance sheet. The science case for VK2735 is unchanged by the raise; the per-share claim on that science is not. This article is for informational purposes only and does not constitute investment advice.

Sep 23 2026, 20:56

S&P 500 slides as 10-year Treasury yield tops 5%

The S&P 500 fell 1.4% to 5,412 on Wednesday, its steepest one-day drop in six weeks, after the 10-year Treasury yield climbed 16 basis points to 5.12% — the first close above 5% since July 2007. The Nasdaq Composite lost 2.1% to 17,084 and the Dow Jones Industrial Average slipped 0.9% to 42,310, as traders priced in another Federal Reserve rate increase before year-end. "The 10-year at 5.12% is the whole story — it resets the discount rate on every cash flow in the index, and the longest-duration names feel it first," said Priya Mehta, head of equity market structure at Edgen Research. "Until the long end stabilizes, rallies are going to be sold into." The damage was concentrated where valuations depend most on distant earnings. Technology fell 2.6% and communication services dropped 2.2%, with consumer discretionary down 1.8%. Defensive corners held: utilities slipped 0.3%, consumer staples lost 0.4% and energy added 0.2% as Brent crude rose 1.1% to $94.60 a barrel. Roughly 3,900 New York Stock Exchange issues declined against 1,100 that advanced, and composite volume ran about 18% above the 20-day average. The VIX jumped 2.4 points to 21.6, its highest since August and above its one-year median of 17.4. The move began in the bond market. Yields rose across the curve as investors sold Treasuries, with the 30-year climbing 14 basis points to 5.28% and the two-year up 9 basis points to 5.06%, flattening the 2s10s spread to 6 basis points. The dollar strengthened alongside the selloff, with the DXY index up 0.6% to 107.4, while gold fell 0.8% to $2,612 an ounce as higher real rates raised the opportunity cost of holding bullion. Traders pointed to three catalysts: a run of firm economic data that pushed back the timing of Fed cuts, heavy Treasury supply as the deficit widens, and a repricing of the terminal rate above 5.5% in futures markets. Fed funds futures now assign a 46% probability to another quarter-point increase at the November meeting, up from 28% a week earlier, according to CME Group data. ## Rate-Sensitive Names Take the Brunt The rotation was visible beneath the index level. Regional banks fell 3.1% as the gap between deposit costs and loan yields narrowed, and homebuilders dropped 4.2% with the average 30-year mortgage rate near 7.9%. Real estate investment trusts lost 2.8%. Utilities' relative resilience reflected their regulated, bond-like cash flows rather than any improvement in demand. Small caps underperformed sharply, with the Russell 2000 down 2.4% to 2,148, because smaller companies carry a higher share of floating-rate debt. The equal-weighted S&P 500 fell 1.1%, less than the cap-weighted index, confirming that the largest technology names drove the decline. ## What a Sustained 5% Yield Means A 10-year yield held above 5% compresses equity multiples mechanically. At a 5.12% risk-free rate, the S&P 500's forward earnings yield of roughly 5.4% leaves an equity risk premium near 0.3 percentage point, close to the narrowest since 2002. That gap has historically preceded either a decline in bond yields or a de-rating in stock prices. The next test comes on Nov. 7, when the Fed announces its rate decision, followed by the October consumer price index on Nov. 13. A core reading above 0.3% month over month would likely push the 10-year toward 5.25%, a level last seen in June 2007. Corporate borrowers are already adjusting: investment-grade spreads widened 4 basis points to 112 basis points, and the pace of new high-yield issuance slowed to $2.1 billion this week from a $6.8 billion weekly average this year. This article is for informational purposes only and does not constitute investment advice.

Sep 23 2026, 20:55

Dow falls 352 points as 10-year Treasury yield tops 5.1%

A 16-basis-point jump in the 10-year Treasury yield to 5.12% — the highest since July 2007 — knocked US equities lower on Wednesday, with the Dow Jones Industrial Average shedding 352.10 points, or 0.68%, to finish at 51,511.59. The bond move forced investors to reprice the discount rate applied to every future cash flow in the index. "The long end is doing the tightening for the Fed, and equities have to catch up to that arithmetic," said Priya Mehta, head of equity market structure research at Edgen. "When the risk-free rate moves 16 basis points in a session, every duration-heavy multiple in the index is marked down the same day." The move was not confined to the headline index. Rate-sensitive corners of the market absorbed the worst of it, with real estate, utilities and consumer discretionary names leading declines as investors cut exposure to businesses whose valuations depend most on the cost of capital. Energy and financials held up better, helped by the same higher-for-longer rate path that hurt long-duration growth stocks. Trading volume ran above the 20-day average as the selling broadened through the afternoon, and the CBOE Volatility Index rose, though it stayed well below the panic levels of prior rate shocks. The catalyst was explicit rather than atmospheric: a bond market that is now pricing a meaningful probability that the Federal Reserve raises rates again at its October meeting. That expectation had been building through the week, and Wednesday's yield move converted it from a talking point into a valuation input. The dollar firmed against a basket of major currencies as the yield advantage widened, while gold slipped as the opportunity cost of holding a non-yielding asset climbed. Crude oil also softened, with demand concerns tied to tighter financial conditions outweighing supply-side support. ## Why 5.12% matters more than the 352-point drop The Dow's point decline is the visible symptom; the yield is the cause. A 10-year yield above 5% resets the reference rate used across equity valuation models, and the effect compounds with duration. Long-duration growth and technology names, whose cash flows sit furthest in the future, carry the largest sensitivity, which is why the Nasdaq complex underperformed the Dow on a percentage basis even as the Dow's absolute point loss drew the headlines. The transmission runs through three channels. First, higher yields raise the discount rate applied to earnings, compressing price-to-earnings multiples without any change in the underlying business. Second, they raise corporate borrowing costs, which pressures capital-intensive sectors and companies carrying floating-rate debt. Third, they tighten financial conditions broadly, which slows the demand backdrop that revenue forecasts depend on. All three were in play on Wednesday. The October FOMC meeting is now the fixed point around which positioning will be built. Between now and then, the market will trade on incoming inflation and labor data, each release capable of shifting the implied odds of another hike. For portfolio managers, the practical question is whether 5% on the 10-year is a ceiling or a waypoint — a distinction that determines whether this week's selling is a buying opportunity in rate-sensitive sectors or the start of a deeper multiple compression across US indices. The cross-asset picture reinforces the rates-first reading. A firmer dollar and softer gold are the classic signatures of a real-yield move rather than a growth scare, and that combination tends to weigh on emerging market assets and dollar-denominated commodities as well. If the 10-year holds above 5%, the pressure extends beyond US equities into global risk assets, including crypto, which trades as a long-duration risk proxy in this regime. This article is for informational purposes only and does not constitute investment advice.